Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080689 · ClinicalTrials.gov registry record · NA
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
A NA study of Prostate Cancer, sponsored by GenomeDx Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 286
- Enrollment target
- 19
- Study locations
NCT02080689: Completed NA study of Prostate Cancer, sponsored by GenomeDx Biosciences.
NCT02080689 is a NA study of Prostate Cancer that has completed, run by GenomeDx Biosciences. The registered enrollment target is 286 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (53% lower). The trial reports 19 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02080689, a NA study of Prostate Cancer, has completed, sponsored by GenomeDx Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 286 participants
- Enrollment target
- 19
- Study locations
Study Summary
The influence of Decipher test on urologist and patient treatment plan choices immediately post RP and at the time of PSA rise or BCR
Conditions Studied
Interventions
- OTHER Decipher
Study Locations (19)
Florida
- Urological Research Network - Hialeah
- Lakeland Regional Health Systems - Lakeland
- University of Miami Miller School of Medicine - Miami
Pennsylvania
- Lancaster Urology - Lancaster
- Thomas Jefferson University - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Colorado
- University of Colorado, Denver Medical Campus - Aurora
- The Urology Center of Colorado - Denver
Alaska
- Alaska Urology Institute Alaska Clinical Research Center - Anchorage
California
- Cedars-Sinai Medical Center - Los Angeles
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- Spectrum Health Medical Group - Grand Rapids
New Jersey
- Delaware Valley Urology, LLC - Voorhees Township
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-02-01 |
| Phase | NA |
What the finished NCT02080689 record still lists
NCT02080689 is an interventional study that assigns participants to a tested intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Decipher is the first listed.
NCT02080689 lists 19 locations in 14 states (Florida, Pennsylvania, Colorado).
Frequently Asked Questions
What is clinical trial NCT02080689 about?
NCT02080689 is a clinical study titled "Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery". The influence of Decipher test on urologist and patient treatment plan choices immediately post RP and at the time of PSA rise or BCR
What is the current status of trial NCT02080689?
This trial is currently completed. It is a NA study. The enrollment target is 286 participants. The study started on 2014-05. Estimated completion is 2017-02-01.
What conditions does trial NCT02080689 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02080689?
The interventions under investigation include: Decipher (OTHER).
Who is sponsoring clinical trial NCT02080689?
This trial is sponsored by GenomeDx Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02080689 being conducted?
This trial has 19 study locations across Alaska, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02080689's enrollment target sits among peer trials
286 172nd of 735 higher than 564 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT04936529 · 286 participants · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia